M&A Deal Summary

Lilly Acquires Novartis Animal Health

On April 22, 2014, Lilly acquired life science company Novartis Animal Health from Novartis for 5.4B USD

Acquisition Highlights
  • This is Lilly’s 10th transaction in the Life Science sector.
  • This is Lilly’s 3rd largest (disclosed) transaction.
  • This is Lilly’s 1st transaction in Switzerland.

M&A Deal Summary
Date 2014-04-22
Target Novartis Animal Health
Sector Life Science
Buyer(s) Lilly
Sellers(s) Novartis
Deal Type Divestiture
Deal Value 5.4B USD
Advisor(s) Goldman Sachs (Financial)
Freshfields Bruckhaus Deringer (Legal)

Target

Novartis Animal Health

Basel, Switzerland
Novartis Animal Health, Inc. offers innovative, high-quality medicines to improve the quality of life, health and welfare of animals around the world. For pets, the Company's products offer effective aids to treat some internal and external parasites, prevent heartworm and flea infestations and treat ailments such as arthritic pain and kidney, heart and allergic diseases. For farm animals, Novartis Animal Health offers therapeutic products to treat parasitic and bacterial diseases and are also continually developing new vaccines to prevent diseases in livestock and farmed fish.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Lilly

Indianapolis, Indiana, United States
Category Company
Founded 1876
Sector Life Science
Employees43,000
Revenue 34.1B USD (2023)
DESCRIPTION
Entrance to Eli Lilly's campus in Indianapolis, Indiana.
Entrance to Eli Lilly's campus in Indianapolis, Indiana.

Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Eli Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. Eli Lilly's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Eli Lilly manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.

DEAL STATS #
Overall 17 of 34
Sector (Life Science) 10 of 27
Type (Divestiture) 4 of 6
Country (Switzerland) 1 of 1
Year (2014) 1 of 1
Size (of disclosed) 3 of 20
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-04-17 Siemens Medical Solutions - Two Investigational Positron

United States

Siemens Medical Solutions - Two Investigational Positron Emission Tomography (PET) Tracers comprises two investigational positron emission tomography (PET) tracers, intended to image the neurofibrillary tangles in the brain for the diagnostics of Alzheimer's disease.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-10-27 Eli Lilly - Sentinel and Spectrum Brands

Indianapolis, Indiana, United States

Virbac would acquire a combination of titles and rights for the United States on trademarks, marketing authorizations, patents, know-how, customer lists and other assets, related to two major parasiticides for dogs: Sentinel® Flavor Tabs and Sentinel® Spectrum, currently marketed in the United States by Novartis Animal Health.

Sell $410M

Seller(S) 1

SELLER

Novartis

Basel, Switzerland
Category Company
Founded 1996
Sector Life Science
Employees104,323
Revenue 46.7B USD (2023)
DESCRIPTION
Novartis' corporate campus in Basel, Switzerland.
Novartis' corporate campus in Basel, Switzerland.

Novartis is a global healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.

DEAL STATS #
Overall 3 of 7
Sector (Life Science) 3 of 4
Type (Divestiture) 2 of 6
Country (Switzerland) 2 of 5
Year (2014) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-02-17 CoStim Pharmaceuticals

Boston, California, United States

CoStim is is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-06-29 Spinifex Pharmaceuticals

Stamford, Connecticut, United States

Spinifex Pharmaceuticals, Inc. is a US-Australian biotechnology company developing new drug candidates for the treatment and management of chronic pain.

Buy $200M
Mergr

Product

Company

Legal